Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (12321)	11/23/1999 2:56:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

I wonder if the placebo "a" will have a higher mortaliity rate then the placebo " b" arm in head to head trial between two identical placebos. This after we would have to sit thru several years of dsmb's scutiney, a trial end waiting period, months to crunch the blinded data on some crays to compare the groups, analysis of the analysis, fda submission, reciepts, vacations and holidays. If and i stress (not literally) that the fda did accept submission of the plaecbo data as adequate, then we would have to consider manufactor in cost effective quanitys, stability, half life, and allotment should overwhelming demand develop for the most effective placebo. All IMO. Oh yeah, then we might have to worry about if the company would/did selectively disclose the best placebo data to wohonka. VBG